Citation Impact
Citing Papers
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
2011
Risk of being killed by police use of force in the United States by age, race–ethnicity, and sex
2019 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
2018
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
2009
The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial
2009
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer
2007
Beta-thalassemia
2010
Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium
2008
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver
2004
Control of cancer-related anemia with erythropoietic agents:a review of evidence for improved quality of life and clinical outcomes
2003
Leishmaniasis
2018 Standout
Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer
2011
Intracerebral haemorrhage
2009 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Leishmaniasis in immunosuppressed individuals
2014
Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability
2005
Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
2012
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
2010
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
2007
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
2006
The Cost-Effectiveness of Extended-Duration Antithrombotic Prophylaxis After Total Hip Arthroplasty
2007
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
2004
Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas
2007
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data
2007
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders
2004
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients
2000
Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip Surgery
2000
A structure-based computational workflow to predict liability and binding modes of small molecules to hERG
2020 StandoutNobel
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
2010
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
Microparticles in Cancer
2010
The genetics of venous and arterial thromboembolism
2001
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
2013 Standout
Crohn's disease
2016 Standout
Bisphosphonates in breast cancer
2005
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
2002 Standout
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
2006
Haemochromatosis
2018
Prevention of Venous Thromboembolism
2004 Standout
Calmodulin as a Versatile Tag for Antibody Fragments
1995 StandoutNobel
Bone Marrow Histopathology in Myeloproliferative Disorders—Current Diagnostic Approach
2005
Sickle-cell disease
2010 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
2010
Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoieticbone marrow histology
2006
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
2014 Standout
Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
2008
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
<i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions
2011
Thalidomide
2004
Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors
2010
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
2017 Standout
Glucose-6-Phosphate Dehydrogenase Deficiency
2016
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
The chronic myeloproliferative disorders: Clonality and clinical heterogeneity
2004
The global burden of IBD: from 2015 to 2025
2015 Standout
Biologic agents for IBD: practical insights
2015
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
2007
Chemotherapy-induced thrombosis
2006
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
2010
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
2005 StandoutNature
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
Anemia of Chronic Disease
2005 Standout
Factor V Leiden: A Clinical Review
2001
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Extracellular vesicles: Exosomes, microvesicles, and friends
2013 Standout
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
2009
Head and Neck Cancer
2020 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Human Non–Small Cell Lung Cancer
2006
The Tumor Lysis Syndrome
2011 Standout
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment
2008
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
2011
Comparing the Costs, Risks, and Benefits of Competing Strategies for the Primary Prevention of Venous Thromboembolism
2004
Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
2004
Anticoagulation or Inferior Vena Cava Filter Placement for Patients With Primary Intracerebral Hemorrhage Developing Venous Thromboembolism?
2003
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
2007 Standout
How I treat transfusional iron overload
2012
Myeloproliferative disorders
2008
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
2016 Standout
mice: Multivariate Imputation by Chained Equations inR
2011 Standout
Iron-Deficiency Anemia
2015 Standout
Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases
2017
Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era
2011
Glucose-6-phosphate dehydrogenase deficiency
2008 Standout
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
2007
How I manage patients with atypical microcytic anaemia
2012
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
2008
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Fast gel electrophoresis to analyze DNA-protein interactions.
1990
Thalidomide Use and Digital Gangrene
2006
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
2009
Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis
2010
Works of Monia Marchetti being referenced
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
2002
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).
2004
Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2007
Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis
2001
Chronic Myeloproliferative Disorders
2003
Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment
2011
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
2001
Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease
2012
Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses
2014
Consensus conference on the management of tumor lysis syndrome
2008
Clinical and Economic Issues in the Treatment of Advanced Breast Cancer with Bisphosphonates
2003
Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies
2002
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian national health service
2004
Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process
2011
Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia
1998
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
2009
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders
2008
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia
2007
Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease
2011
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
2004
Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia
2001
Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2–Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia
2005
PO-35 Loss of angiogenic activity and improvement of hemostatic variables in patients with gastrointestinal stromal tumors (GIST) under Imatinib therapy: a biological evaluation
2010
Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
1999
Extended Anticoagulation for Prevention of Recurrent Venous Thromboembolism in Carriers of Factor V Leiden
2000
Identification of new BMP6 pro‐peptide mutations in patients with iron overload
2017
Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost–utility analysis
2011
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
2006
High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy.
2002
Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial
2004
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
2007